Part VI: Summary of the risk management plan

Summary of risk management plan for Thalidomide Accord 50 mg hard capsules (Thalidomide)

This is a summary of the risk management plan (RMP) for Thalidomide Accord 50 mg hard capsules. The RMP details important risks of Thalidomide Accord 50 mg hard capsules, how these risks can be minimised, and how more information will be obtained about Thalidomide Accord 50 mg hard capsule's risks and uncertainties (missing information).

Thalidomide Accord 50 mg hard capsule's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Thalidomide Accord 50 mg hard capsule should be used.

This summary of the RMP for Thalidomide Accord 50 mg hard capsules should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Thalidomide Accord 50 mg hard capsule's RMP.

I. The medicine and what it is used for

Thalidomide Accord 50 mg hard capsules in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Thalidomide Accord 50 mg hard capsules, together with measures to minimise such risks and the proposed studies for learning more about Thalidomide Accord 50 mg hard capsule's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In the case of Thalidomide Accord 50 mg hard capsules, these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Thalidomide Accord 50 mg hard capsules is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Thalidomide Accord 50 mg hard capsules are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of thalidomide Accord 50 mg hard capsules. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorisation Holder

Important identified risks	• Teratogenicity • • Severe infections (sepsis, septic shock and viral reactivation of hepatitis B) • Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS
Important potential risks	• Ischaemic heart disease (including myocardial infarction) • Other second primary malignancies (SPM) • Hepatic disorders (hepatocellular and cholestatic liver injury) • Off-label use
Missing information	• None

II.B Summary of important risks

Important Identified Risks: **Teratogenicity**	
Risk minimisation measures	Routine risk minimisation measures: Section 4.3, 4.4, 4.6, 4.8 and 5.3 of Thalidomide SmPC and corresponding section of PIL has information on this safety concern. Other routine risk minimisation measures include the prescription only status of the product. Additional risk minimisation measures: **Pregnancy Prevention Programme (PPP)** • Educational Programme o Direct HCP communication prior to launch o Educational material for healthcare professionals and patients ✓ HCP booklets, patient assessment algorithm, patient treatment initiation forms, patient card or equivalent tools.

	✓ Patient booklets • Therapy management: o Criteria for determining women of childbearing potential (WCBP), effective contraceptive measures for WCBP, regular pregnancy testing for WCBP o Advise provided by SPC, outlined in direct HCP communication and detailed in Educational materials. o Controlled distribution system
Additional pharmacovigilance activities	Additional pharmacovigilance activities: Category 3 study for the assessment of the effectiveness of the Pregnancy Prevention Programme (PPP) of Thalidomide Accord 50 mg hard capsules
Important Identified Risks: **Severe infections (sepsis, septic shock and viral reactivation of hepatitis B)**	
Risk minimisation measures	Routine risk minimisation measures: Section 4.4 and 4.8 of Thalidomide SmPC and corresponding section of PIL has information on this safety concern. Other routine risk minimisation measures include the prescription only status of the product. Additional risk minimisation measures: DHCP communication letter
Important Identified Risks: **Acute myeloid leukaemia and myelodysplastic syndromes**	
Risk minimisation measures	Routine risk minimisation measures: Section 4.4 and 4.8 of Thalidomide SmPC and corresponding section of PIL has information on this safety concern. Other routine risk minimisation measures include the prescription only status of the product. Additional risk minimisation measures: DHCP communication letter
Important Potential Risk: Ischaemic heart disease (including myocardial infarction)	
Risk minimisation measures	Routine risk minimisation measures:

	Section 4.4 and 4.8 of Thalidomide SmPC and corresponding section of PIL has information on this safety concern. Other routine risk minimisation measures include the prescription only status of the product. Additional risk minimisation measures: Educational material for HCPs and patients
Important Potential Risk: Other second primary malignancies	
Risk minimisation measures	Routine risk minimisation measures: Section 4.4 of Thalidomide SmPC and corresponding section of PIL has information on this safety concern. Other routine risk minimisation measures include the prescription only status of the product. Additional risk minimisation measures: DHCP communication letter
Important Potential Risk: Off-label use	
Risk minimisation measures	Routine risk minimisation measures: Other routine risk minimisation measures include the prescription only status of the product Additional risk minimisation measures: DHCP communication letter, Educational material for healthcare professionals and patients
Additional pharmacovigilance activities	Additional pharmacovigilance activities: Category 3 study for the monitoring of off-label use of Thalidomide Accord 50 mg hard capsules

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no proposed studies which are conditions of the marketing authorisation or specific obligation of Thalidomide Accord 50 mg hard capsules.

II.C.2 Other studies in post-authorisation development plan

Study short name	Purpose of the study
Pregnancy Prevention Programme (PPP) of Thalidomide Accord 50 mg hard capsules (Category 3 Study)	For the assessment of the effectiveness of PPP
Monitoring of off-label use of Thalidomide Accord 50 mg hard capsules (Category 3 Study)	To monitor off-label use of Thalidomide